Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
<p><strong>Background:</strong><br /> Prostate cancer is the most common cancer among men in the UK. Prostate-specific antigen testing followed by biopsy leads to overdetection, overtreatment as well as undertreatment of the disease. Evidence of treatment effectiveness has la...
Main Authors: | Hamdy, FC, Donovan, JL, Lane, JA, Mason, M, Metcalfe, C, Peter Holding, Wade, J, Noble, S, Garfield, K, Young, G, Davis, M, Peters, TJ, Turner, EL, Martin, RM, Oxley, J, Robinson, M, Staffurth, J, Walsh, E, Blazeby, J, Bryant, R, Bollina, P, Catto, J, Doble, A, Doherty, A, Gillatt, D, Gnanapragasam, V, Hughes, O, Kockelbergh, R, Kynaston, H, Paul, A, Paez, E, Powell, P, Prescott, S, Rosario, D, Rowe, E, Neal, D |
---|---|
Other Authors: | ProtecT Study Group |
Format: | Journal article |
Language: | English |
Published: |
NIHR Journals Library
2020
|
Similar Items
-
Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT
by: Hamdy, F, et al.
Published: (2018) -
Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
by: Brewster, S, et al.
Published: (1999) -
Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
by: Johnston, T, et al.
Published: (2016) -
Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
by: Neal, D, et al.
Published: (2019) -
The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
by: Young, GJ, et al.
Published: (2020)